List of Excipients in Branded Drug DIETHYLPROPION HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Apotheca Inc	DIETHYLPROPION HYDROCHLORIDE	diethylpropion hydrochloride	12634-530	LACTOSE
Apotheca Inc	DIETHYLPROPION HYDROCHLORIDE	diethylpropion hydrochloride	12634-530	MAGNESIUM STEARATE
Apotheca Inc	DIETHYLPROPION HYDROCHLORIDE	diethylpropion hydrochloride	12634-530	STARCH, CORN

Generic Drugs Containing DIETHYLPROPION HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Lannett Company Inc	diethylpropion hydrochloride	0527-1475	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	diethylpropion hydrochloride	0527-1475	LACTOSE MONOHYDRATE
Lannett Company Inc	diethylpropion hydrochloride	0527-1475	MANNITOL

What are the Most Frequently-Used Excipients in DIETHYLPROPION HYDROCHLORIDE?

# Of NDCs	Excipient
10	CARBOMER HOMOPOLYMER TYPE A
7	CELLULOSE, MICROCRYSTALLINE
10	CROSPOVIDONE

Last updated: August 10, 2026

Diethylpropion hydrochloride is a mature, low-cost sympathomimetic anorectic with limited branded value and no apparent blocking patent estate. Commercial opportunity is concentrated in generic supply, differentiated release profiles, excipient-controlled tolerability, preservative-free or allergy-conscious formulations, contract manufacturing, and expansion into markets where short-term obesity treatments remain available. The main barriers are controlled-substance compliance, limited clinical demand, unfavorable reimbursement, competition from newer anti-obesity medicines, and the need to demonstrate bioequivalence for modified-release products.

Diethylpropion Hydrochloride Excipient Strategy, Patent Position, and Commercial Opportunities

What is diethylpropion hydrochloride used for?

Diethylpropion hydrochloride is a sympathomimetic amine indicated as a short-term adjunct to caloric restriction for weight reduction in patients with an initial body mass index meeting the product-label criteria. The drug is generally prescribed for a few weeks rather than as chronic obesity therapy. It is available in immediate-release and extended-release forms.

Attribute	Diethylpropion hydrochloride
Active ingredient	Diethylpropion hydrochloride
Pharmacologic class	Sympathomimetic amine anorectic
Common strengths	25 mg immediate-release; 75 mg extended-release
Historical U.S. brands	Tenuate; Tenuate Dospan
Regulatory category	Prescription drug; controlled substance
U.S. controlled-substance schedule	Schedule IV
Primary dosage forms	Tablets and extended-release tablets or capsules, depending on manufacturer
Indication	Short-term adjunct in obesity management
Biosimilar relevance	None
Current innovation center	Generic formulation, supply reliability, release control, and market access

The FDA labeling for Tenuate and Tenuate Dospan describes diethylpropion as a centrally acting sympathomimetic agent and limits its use to short-term therapy because of dependence, cardiovascular, and central nervous system risks [1, 2].

What excipients are used in diethylpropion hydrochloride products?

Excipient composition varies by manufacturer, dosage form, and market. Historical immediate-release formulations have used lactose, corn starch, povidone, talc, and magnesium stearate. Extended-release products require a matrix, coating, or other release-controlling system that changes the excipient strategy.

Immediate-release formulation excipients

A conventional 25 mg tablet can use a standard wet-granulation or direct-compression platform:

• Lactose or microcrystalline cellulose as diluent
• Corn starch or pregelatinized starch as disintegrant
• Povidone as binder
• Croscarmellose sodium or sodium starch glycolate as modern disintegrants
• Colloidal silicon dioxide as glidant
• Magnesium stearate or sodium stearyl fumarate as lubricant
• Film coating based on hypromellose, polyethylene glycol, titanium dioxide, and colorants

Historical Tenuate labeling lists lactose, corn starch, povidone, talc, and magnesium stearate among inactive ingredients [1]. A generic manufacturer can preserve the legacy formulation or adopt a lower-risk excipient system that improves manufacturability and addresses patient sensitivities.

Extended-release formulation excipients

The 75 mg extended-release product requires tighter control of drug release, dose uniformity, and tablet or capsule performance. Potential technologies include:

• Hydrophilic polymer matrices using hypromellose
• Insoluble matrix systems using ethylcellulose or ammonio methacrylate copolymers
• Coated multiparticulates
• Osmotic or diffusion-controlled systems
• Lipid-based matrices
• Granule coating with a polymeric rate-controlling membrane

The commercial value of an extended-release formulation depends less on the active ingredient than on release kinetics, manufacturing reproducibility, and regulatory comparability. A formulation that releases too rapidly can increase peak exposure and stimulant-related adverse effects. A formulation that releases too slowly can reduce clinical effect or create an unacceptable food-effect profile.

What excipient strategy is most commercially attractive?

The strongest near-term strategy is a robust, low-cost immediate-release tablet paired with a differentiated extended-release platform. The two products should not necessarily use the same excipient system.

Immediate-release strategy

For a 25 mg tablet, a manufacturer can prioritize:

1. Low raw-material cost.
2. High tablet hardness with rapid disintegration.
3. Low weight variability at a relatively low drug load.
4. Low sensitivity to lubricant overmixing.
5. Broad supplier availability.
6. Minimal dependence on animal-derived or allergenic materials.

A lactose-free formulation using microcrystalline cellulose, mannitol, or dibasic calcium phosphate may support institutional and pharmacy purchasing requirements. The commercial benefit is likely incremental rather than transformational because many generic buyers prioritize price and supply continuity over excipient differentiation.

Extended-release strategy

For a 75 mg product, the formulation should prioritize:

• Consistent dissolution across pH conditions
• Low batch-to-batch variability
• Controlled alcohol interaction risk
• Resistance to dose dumping
• Stable release after long-term storage
• Manufacturability at commercial scale
• A manageable bioequivalence program

A hydrophilic matrix based on hypromellose is often the most practical platform because it is widely available and compatible with conventional tablet manufacturing. A multiparticulate system may provide better control of dose dumping and food effects but has higher manufacturing complexity and development cost.

Excipient positioning opportunities

Potential differentiated products include:

Product concept	Commercial rationale	Main development issue
Lactose-free immediate-release tablet	Addresses excipient sensitivity and institutional procurement	Limited willingness to pay
Dye-free tablet	Supports allergy-conscious and pediatric-household positioning	May reduce product identification
Smaller 25 mg tablet	Improves swallowability and dose titration	Requires tablet-content uniformity control
Extended-release matrix tablet	Reduces dosing frequency	Bioequivalence and dissolution complexity
Abuse-deterrent or tamper-resistant platform	May support controlled-substance risk management	High cost and uncertain reimbursement
Blister-pack presentation	Reduces diversion and supports adherence	Packaging cost
Low-moisture formulation	Improves stability in humid markets	Packaging and process validation requirements

What patents protect diethylpropion hydrochloride?

The original diethylpropion compound and its legacy branded formulations are old products. Public FDA records do not indicate a current, commercially meaningful composition-of-matter patent blocking generic development in the United States. The historic Tenuate and Tenuate Dospan products were approved many decades ago, well before the modern generic litigation environment.

The practical IP landscape is therefore formulation-specific rather than molecule-specific.

IP category	Current commercial relevance
Composition-of-matter patent	No apparent blocking U.S. patent for the old active ingredient
Original product patent	Expected to be expired
Immediate-release formulation patent	Limited relevance unless a particular modern formulation is patented
Extended-release formulation patent	Potentially relevant if an unexpired product-specific patent exists
Method-of-use patent	Limited value for the established short-term obesity indication
Manufacturing patent	Could protect process efficiency or impurity control, but likely narrow
Trade secret	Potentially important for release control, granulation, and scale-up
Regulatory exclusivity	No meaningful current exclusivity expected for legacy products

The FDA Orange Book must be reviewed by product and applicant because listings can change, and some generic products may have different dosage forms or reference-product relationships [3]. The absence of a visible blocking patent does not eliminate the need to review formulation patents, foreign rights, pending applications, and freedom-to-operate risks.

When does diethylpropion hydrochloride lose exclusivity?

Diethylpropion hydrochloride has already passed its core U.S. patent and regulatory exclusivity period. The commercial question is no longer a loss-of-exclusivity event. It is whether a manufacturer can secure or maintain an approved generic product and compete economically.

The relevant timeline is:

Milestone	Timing
Original U.S. approvals	Mid-20th century
Tenuate and Tenuate Dospan commercialization	Historical
Core patent protection	Expired
Generic availability	Established
Current exclusivity issue	No material remaining NCE or patent exclusivity expected
Current market risk	Supply interruption, controlled-substance compliance, and demand erosion

Diethylpropion does not have biosimilar exclusivity because it is a small-molecule drug. Any competitor would use the abbreviated new drug application pathway rather than a biosimilar pathway.

What is the Orange Book status of diethylpropion hydrochloride?

The Orange Book status should be assessed separately for immediate-release and extended-release reference products. The reference listed drugs associated with Tenuate and Tenuate Dospan are legacy products, and generic applications may be listed against the relevant reference product depending on dosage form and approval history [3].

Key Orange Book issues include:

• Whether a specific 25 mg tablet has a currently active reference listed drug.
• Whether the 75 mg extended-release product is listed as a tablet, capsule, or another dosage form.
• Whether any patents or exclusivity codes remain listed.
• Whether an ANDA applicant must demonstrate equivalence to an immediate-release or extended-release reference.
• Whether discontinued reference products create a reference-product or suitability petition issue.

A commercial diligence review should not assume that an immediate-release product can be substituted for an extended-release reference. FDA approval, labeling, dissolution, and bioequivalence requirements remain dosage-form specific.

Are Paragraph IV challenges relevant to diethylpropion hydrochloride?

Paragraph IV litigation risk appears limited because the core product estate is old and the major commercial value is in generic supply rather than a protected branded product. A Paragraph IV filing could still arise if a company develops a new extended-release formulation and an unexpired patent is listed against the relevant reference product.

Potential scenarios include:

1. A generic applicant certifies that a listed formulation patent is invalid.
2. A generic applicant certifies noninfringement because its release-control system uses different polymers or coating architecture.
3. A patent owner brings litigation after receiving a Paragraph IV notice.
4. The parties settle with an agreed launch date.
5. The FDA approves the ANDA after the statutory review and litigation framework is satisfied.

No major current Paragraph IV dispute is identified in the public legacy-product record reviewed for this analysis. The principal risk is a future formulation patent associated with a specific extended-release product, not a challenge to the old active ingredient.

What patent litigation and settlement agreements affect the product?

No material current U.S. patent litigation or settlement agreement appears to define the commercial market for legacy diethylpropion hydrochloride products. Historical product litigation, if any, would have limited relevance unless it established enforceable rights over a particular release-control technology.

The more important legal issues are:

• Controlled-substance registration and recordkeeping
• Manufacturing quotas and inventory controls
• Diversion monitoring
• Product-liability exposure
• Labeling compliance
• Advertising restrictions
• State pharmacy and prescribing rules
• Contractual supply obligations

For a new extended-release product, litigation exposure would increase if the formulation relied on a patented polymer architecture, coated-pellet process, abuse-deterrent design, or proprietary manufacturing step.

What FDA regulatory requirements apply to diethylpropion hydrochloride?

Diethylpropion hydrochloride products are prescription drugs and Schedule IV controlled substances in the United States. FDA labeling warns against use in patients with certain cardiovascular conditions, hyperthyroidism, glaucoma, severe hypertension, or a history of drug abuse, subject to the specific product label [1, 2].

A new generic immediate-release product would generally require:

• ANDA submission
• Pharmaceutical equivalence
• Bioequivalence
• Stability data
• Chemistry, manufacturing, and controls information
• Controlled-substance compliance
• Labeling consistent with the reference product

An extended-release product would require more demanding comparative dissolution and pharmacokinetic evidence. FDA may scrutinize partial-area exposure, food effects, dose proportionality, alcohol interaction, and the impact of manufacturing changes on release performance.

The active ingredient has no biosimilar pathway. A 505(b)(2) strategy may be relevant only if the sponsor proposes a meaningful change in dosage form, route, release profile, or clinical use that cannot be supported through a conventional ANDA.

How strong is the patent estate for diethylpropion hydrochloride?

The patent estate is weak for the active ingredient and potentially moderate for a newly developed extended-release formulation.

Dimension	Assessment
Composition-of-matter protection	Very weak or expired
Brand protection	Low
Immediate-release formulation protection	Low
Extended-release formulation protection	Variable; depends on specific technology
Manufacturing IP	Potentially moderate but narrow
Trade-secret protection	Moderate for process parameters and scale-up knowledge
Regulatory exclusivity	Low
Litigation leverage	Low for legacy products
Generic entry barrier	Regulatory and operational rather than patent-based

The most defensible IP strategy would focus on a specific release profile, polymer combination, manufacturing process, impurity-control method, or packaging system. Broad claims covering the active ingredient or ordinary tablet excipients would face validity and obviousness concerns because the molecule and conventional dosage forms are long established.

What generic entry risks exist?

Generic entry risk is already structurally high. A potential entrant faces less patent risk than market risk.

Market risks

• Low unit prices
• Small and declining demand relative to newer obesity medicines
• Limited prescriber use
• Competition from phentermine, phentermine/topiramate, naltrexone/bupropion, GLP-1 receptor agonists, and dual incretin therapies
• Controlled-substance distribution costs
• Pharmacy stocking constraints
• Product discontinuation risk if volumes fall below efficient scale

Manufacturing risks

• Low-dose content uniformity for 25 mg tablets
• Cross-contamination controls for potent sympathomimetic compounds
• Extended-release dissolution variability
• Polymer and coating raw-material variability
• Stability in hot and humid climates
• Controlled-substance inventory reconciliation
• API availability and supplier qualification

Commercial launch scenarios

Scenario	Likely outcome
Lowest-cost immediate-release generic	Rapid price competition and limited margin
Reliable dual-source supply	Moderate opportunity with wholesalers and institutions
Differentiated extended-release product	Higher margin potential, slower development
Specialty-pharmacy or cash-pay product	Niche demand with limited scale
International registration strategy	Opportunity where legacy anorectics remain accepted
Reformulated controlled-release product	Higher regulatory and IP cost, uncertain uptake

Which companies are competing with diethylpropion hydrochloride?

Competition is primarily therapeutic and generic rather than branded. The relevant competitive set includes:

• Phentermine
• Diethylpropion
• Benzphetamine
• Phendimetrazine
• Naltrexone/bupropion
• Phentermine/topiramate
• Semaglutide
• Tirzepatide
• Liraglutide

Older sympathomimetics compete on low acquisition cost and short-term use. GLP-1 and incretin-based therapies compete on chronic weight-loss efficacy and broader commercial support but have substantially higher cost, administration, and access requirements.

Competitive factor	Diethylpropion	Newer chronic obesity medicines
Acquisition cost	Low	High
Administration	Oral	Often injectable
Treatment duration	Short-term label	Chronic treatment
Controlled substance	Yes	Generally no
Clinical infrastructure	Simple	More intensive
Patent barriers	Low	Often substantial
Reimbursement pressure	High	High, but growing coverage
Commercial growth	Limited	Stronger market expansion

The commercial opportunity is greatest in cash-pay, low-cost, short-duration treatment settings and markets where newer therapies are unavailable or unaffordable.

What licensing deals could create value?

Licensing opportunities are more likely to involve manufacturing and distribution than molecule-level rights. Relevant structures include:

• Regional licensing of an approved generic
• Contract manufacturing and supply agreements
• API sourcing and dual-supply arrangements
• Co-development of a controlled-release product
• Private-label distribution through pharmacy groups
• Technology licensing for matrix or multiparticulate release
• Licensing of controlled-substance packaging and diversion-control systems

An attractive deal would require modest upfront investment, guaranteed minimum purchase volumes, and clear responsibility for DEA compliance, pharmacovigilance, recalls, and shortage management. A royalty-heavy structure is less compelling for a low-price generic unless the license covers a differentiated extended-release product.

What geographic opportunities exist?

The product’s international potential depends on whether diethylpropion remains approved and accepted for obesity treatment in each jurisdiction. Regulatory status is not uniform. Some markets restrict or prohibit centrally acting anorectics because of cardiovascular, psychiatric, dependence, or abuse concerns.

Potential geographic screening criteria include:

• Current national marketing authorization
• Controlled-substance classification
• Local obesity-treatment guidelines
• Availability of newer anti-obesity therapies
• Import controls for the API
• Local pharmacovigilance requirements
• Reference-product availability
• Reimbursement and pharmacy distribution

Latin American, selected Asian, and other price-sensitive markets may offer opportunities, but local approval and controlled-drug requirements must be established independently. A U.S. approval does not create automatic international market access.

What revenue exposure does diethylpropion hydrochloride create?

Revenue exposure is likely modest for diversified pharmaceutical companies and more significant for specialized generic suppliers with limited portfolios. The product’s value is sensitive to:

• Annual prescriptions
• Generic price erosion
• Number of active suppliers
• API cost
• Controlled-substance handling expense
• Product discontinuations
• Reimbursement restrictions
• Competition from chronic obesity medicines

A single-source or dual-source position can produce stable niche revenue if supply is reliable. The same position can create concentration risk because a quality event, DEA issue, or API interruption can eliminate sales quickly.

The best commercial thesis is operational rather than patent-driven: maintain approval, secure API supply, control manufacturing cost, and avoid unnecessary formulation complexity.

What manufacturing and IP barriers matter most?

The highest barriers are process and compliance barriers.

Manufacturing barriers

Immediate-release production is technically straightforward, but commercial execution still requires:

• Validated low-dose blending
• Uniformity across batch and tablet weight ranges
• Robust lubrication control
• Adequate stability packaging
• Controlled-substance security
• Reliable API testing and impurity profiling

Extended-release production adds:

• Polymer hydration control
• Granule-size management
• Coating-weight uniformity
• Dissolution-method sensitivity
• Scale-up risk
• Food-effect and alcohol-interaction assessment

IP barriers

A sponsor developing a new formulation should conduct freedom-to-operate searches around:

• Hypromellose matrix systems
• Ethylcellulose coatings
• Multiparticulate release systems
• Abuse-deterrent formulations
• Specific dissolution profiles
• Polymer combinations
• Manufacturing and coating processes
• Controlled-substance packaging

Trade secrets may provide more practical protection than patents for process settings, granulation endpoints, coating parameters, and impurity-control methods.

Key Takeaways

• Diethylpropion hydrochloride is a legacy, low-cost, Schedule IV anorectic with established generic competition.
• Core composition-of-matter and original brand protection are expired or commercially irrelevant.
• The main regulatory pathway is an ANDA for a conventional generic; extended-release products require more complex bioequivalence and dissolution work.
• Immediate-release excipient innovation can address lactose, dye, tablet-size, and supply-chain preferences but is unlikely to support a large premium.
• Extended-release formulation is the clearest technical differentiation opportunity.
• No major current Paragraph IV litigation or settlement appears to define the legacy market.
• Biosimilar risk is irrelevant because diethylpropion is a small molecule.
• Commercial value depends on cost, supply reliability, controlled-substance compliance, and regional demand.
• New formulation patents may provide targeted protection, but broad protection over the active ingredient is not realistic.
• Newer chronic obesity therapies limit long-term growth and reduce the strategic value of the product for major pharmaceutical companies.

Frequently Asked Questions

Can diethylpropion hydrochloride be reformulated as a once-daily product?

Yes. A 75 mg extended-release platform can support once-daily dosing if the formulation meets FDA requirements for release profile, pharmacokinetics, stability, and labeling. The development burden is materially higher than for a 25 mg immediate-release tablet.

Are lactose-free diethylpropion tablets commercially viable?

Potentially, but the opportunity is niche. A lactose-free product may improve procurement access and patient acceptability, yet most buyers are likely to prioritize price, availability, and approved substitution status.

Does diethylpropion hydrochloride require a new chemical entity patent strategy?

No. The active ingredient is a legacy molecule. A viable IP strategy would target a specific formulation, manufacturing process, packaging design, or release-control technology.

Can a manufacturer switch excipients without conducting clinical trials?

A generic manufacturer may change excipients if the product remains pharmaceutically equivalent and meets applicable FDA quality and bioequivalence requirements. Changes to an extended-release system can materially affect dissolution and pharmacokinetics and may require additional comparative studies.

Is diethylpropion hydrochloride a viable platform for a combination obesity product?

The opportunity is limited. A combination product would face pharmacologic safety concerns, controlled-substance considerations, clinical-development costs, and strong competition from established chronic obesity therapies.

References

1. U.S. Food and Drug Administration. (n.d.). Tenuate (diethylpropion hydrochloride) tablets: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Tenuate Dospan (diethylpropion hydrochloride) extended-release tablets: Prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

4. U.S. Food and Drug Administration. (2015). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin: Guidance for industry. FDA.

5. U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules. U.S. Department of Justice.